Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes

Company hopes to file in Europe next year

Executive Summary

Company boosted by animal study which helps answer riddle of improvement in untreated eye.

You may also be interested in...



REFLECT Study Confirms Efficacy Of GenSight's Gene Therapy Lumevoq

French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.

GenSight Undeterred By Gene Therapy’s Placebo Puzzle

Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain

Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut

Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel